Abstract:Objective To observe the effect of recombinant human endostatin (endostar) in combination with radiation on hepatic carcinoma xenografts in mice under different timing of administration, endostar dose and radiation dose.Methods (1) The xenotransplanted tumor model of human hepatic carcinoma in mice was established.The mice were randomly grouped based on timing of administration, endostar dose and radiation dose, with 10 mice in each group.The length and diameter of xenografts were measured every other day.The tumor suppress effect was compared between early administration and late administration manners.(2) The mice were divided into 6 groups with 30 mice in each group and treated in early administration manner.Then the overall survival was observed.(3) MTT assay was used to observe the synergistic effect influenced by the dose of endostar and radiation.(4) Western blotting was used to detect the expression of epidermal growth factor (EGF) and vascular endothelial growth factor receptor-1(Flt-1) in early and late administration manners.(5) Immunochemistry was used to test the expression of vascular endothelial growth factor (VEGF) and KDR, as well as microvascular density of hepatic carcinoma xenografts.(6) Cyto-apoptosis was observed by electron microscope and cell cycles and apoptotic rates were determined by flow cytometry.Results Compared with control group, endostar could suppress the growth of hepatic carcinoma xenografts (P<0.05), and early administration manner performed better than late administration manner (P<0.05).Synergistic effect was found in 8 mg/kg endostar+RT group of early administration manner, and the tumor suppress rate was 58.0%, better than other groups (P<0.05).The median overall survival of 8 mg/kg endostar+RT group was 55.6 days with the life prolonging rate of 29.3%, better than other groups (P<0.05).5 μg/ml endostar in combination with 4Gy radiation on HUVECs cells showed synergistic effect with the proliferative inhibition rate of 59.20%, better than other doses of endostar (P<0.05).200 μg/ml endostar in combination with 4 Gy radiation on HepG2 cells showed synergistic effect with the proliferative inhibition rate of 43.45%, better than other doses of endostar (P<0.05).5 μg/ml endostar in combination with different doses of radiation on HUVECs, as well as 200 μg/ml endostar in combination with different doses of radiation on HepG2 cells both showed better proliferative inhibition rates than using endostar or radiation alone (P<0.05).Western blotting test showed that the expressions of EGF in 8 mg/kg endostar group and 8 mg/kg endostar+RT group of early administration manner was lower than those of late administration manner.However, the expression of Flt-1 between the two manners had no difference (P>0.05).Endostar in combination with radiation could significantly decrease MVD of hepatic carcinoma xenografts, the MVD in 8 mg/kg endostar+RT group was 8.6±1.3, lower than other groups (P<0.05).In 8 mg/kg endostar+RT group, the expression of VEGF and KDR was lower than other groups (P<0.05).Apoptoic changes were observed under lectron microscope in endostar in combination with radiation groups.Flow cytometry showed that cell cycles were blocked in S phase in 8 mg/kg endostar+RT group, and the cyto-apoptotic rate was higher than other groups (P<0.05).Conclusion The synergistic effect of endostar in combination with radiation is correlated to timing of administration, endostar dose and radiation dose, and the effect of early administration of endostar is superior to the late.

Effects of Recombinant Human Endostatin and Docetaxel on MMP and Its Following Anti-neoplastic Effect under Different Administration Sequences

[Observation of the Antitumor Effect of Endostar Combined with Docetaxel under Different Administration Sequences].

An Experimental Research into Endostatin Microbubble Combined with Focused Ultrasound for Anti-Tumor Angiogenesis in Colon Cancer

Comparison of the effects of recombinant human endostatin and docetaxel on human umbilical vein endothelial cells in different growth states.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Therapeutic Efficacy of Recombinant Human Endostatin Combined with Chemotherapeutics in Mice-Transplanted Tumors

The Influences of Endostatin on Bladder Tumor Growth and Its Mechanism

[Biological Effect of Endostatin on Transplanted Human Lung Adenocarcinoma Calu-6 Tumor in Nude Mice].

Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma

Experimental study of anti-gastric cancer effect of combined application of recombinant human endostatin and paclitaxel

Effect of Recombinant Human Endostatin on Antitumor Efficacy of Paclitaxel/Gemcitabine/Cisplatin (tgp) Chemotherapy in the Treatment of Advanced Urothelial Carcinoma

A experimental study on endostatin treatment for breast cancer in mice

Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: Experimental and clinical evidence

The dose and time factors on synergistic effects of the combination of endostar and radiation against hepatic carcinoma xenografts in mice

STUDY OF ANTI-TUMOR EFFECT OF RECOMBINANT HUMAN ENDOSTATIN

Effect of recombinant human endostatin on microenvironment of human lung adenocarcinoma

Short-term therapeutic effect of recombinant human endostatin combined with chemotherapy for advanced gastric cancer: a Meta-analysis

The Antiangiogenetie Effect and Mechanism of ShenMai Injection Combined with Docetaxel on Transplanted Human Carcinoma in Nude Mice